Literature DB >> 18240391

History of haemophilia.

L M Aledort1.   

Abstract

Haemophilia, an ancient disease, now has sophisticated methods for diagnosis and treatment. The genetically missing factors can now be supplied by fractionation of human-derived (HD) plasma or with recombinant technology (r). Making therapeutic choices is complicated by past transfusion-transmitted diseases. HD and r products now have similar safety profiles. Several diseases have only HD products for treatment. These products remain important in our treatment armamentarium.

Entities:  

Mesh：

Year:  2007        PMID： 18240391     DOI： 10.1111/j.1365-2516.2007.01576.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


  4 in total

Review 1.  The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review.

Authors:  Hector E Castro; María Fernanda Briceño; Claudia P Casas; Juan David Rueda
Journal:  Indian J Hematol Blood Transfus       Date:  2012-11-04       Impact factor: 0.900

2.  Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Authors:  Jerry S Powell
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

3.  Murine leukemia virus-derived retroviral vector has differential integration patterns in human cell lines used to produce recombinant factor VIII.

Authors:  Marcela Cristina Correa de Freitas; Aparecida Maria Fontes; Andrielle de Castilho Fernandes; Virginia Picanço-Castro; Elisa Maria de Sousa Russo; Dimas Tadeu Covas
Journal:  Rev Bras Hematol Hemoter       Date:  2014-04-13

4.  School closure in response to epidemic outbreaks: Systems-based logic model of downstream impacts.

Authors:  Dylan Kneale; Alison O'Mara-Eves; Rebecca Rees; James Thomas
Journal:  F1000Res       Date:  2020-05-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.